Breakthrough biotech

Breakthrough biotech

The majority of chief executives I have met while researching this article have chuckled when I told them I am attempting to value biotechnology companies. It’s a fair response – trying to put a tangible value on a company whose products are often barely more than an idea (and a complicated idea at that) is certainly not a simple process. And it is perhaps for this reason that biotech companies in the UK – more conservative and risk-averse than the US – have, so far, failed to gain any real traction.

To continue reading, register today

to enjoy limited access to the following:

  • Daily trading news
  • Funds coverage
  • Features on big investment themes
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now